Helsana HealthInvest

Yazen is a digital healthcare provider focused on delivering personalized weight loss programs, primarily targeting middle-aged men dealing with obesity and potential testosterone deficiencies. The company connects users with a multidisciplinary team of professionals, including doctors, psychologists, dietitians, and personal trainers, to develop customized weight management plans. By leveraging data-driven insights, Yazen incorporates lifestyle changes and, when necessary, medical treatments to enhance both physical and mental well-being. The platform's holistic approach aims to empower individuals to achieve sustainable health improvements through expert guidance and support.

Hedera Dx is a healthcare company established on July 1, 2021, in Epalinges, Vaud, specializing in liquid biopsy solutions aimed at enhancing cancer detection and treatment. The company's innovative system enables hospital laboratories to perform clinically useful liquid biopsies independently, simplifying the process of tumor profiling. By addressing challenges related to compliance, privacy, and validation, Hedera Dx offers a streamlined experience for clinicians, facilitating early detection, therapy selection, and monitoring of cancer recurrence. This technology not only aids in reducing cancer risks but also presents opportunities to lower mortality rates and healthcare costs.

Kenbi is a nurse-centric outpatient care company focused on enhancing the delivery of healthcare services. It provides outpatient care management aimed at supporting nurses and addressing gaps in the healthcare system. By leveraging technology, collegial organizational structures, and human-centric design, Kenbi organizes local care teams to deliver a range of outpatient and at-home services. These services include medical care covered by insurance, as well as household assistance, guidance, and companionship for patients. The company's approach is designed to reduce the time healthcare practitioners spend on bureaucratic tasks, allowing them to focus more on patient care and improving the overall experience for patients and their families.

Entyre GmbH is a healthcare technology company based in Hamburg, Germany, founded in 2017. The company operates an online platform that assists patients and caregivers in navigating bureaucratic processes within the healthcare system. Entyre utilizes proprietary data and algorithms to enhance decision-making for patients, doctors, and insurance companies. Its solutions focus on identifying and rectifying incorrect supplies, thereby improving the quality of outpatient care. By providing technical tools and resources, Entyre aims to empower users to effectively manage the challenges associated with demographic changes in healthcare.

Humanoo is a digital health platform aimed at enhancing the physical and mental well-being of employees and insurance clients. The platform offers customized programs and innovative eHealth solutions in areas such as fitness, physiotherapy, yoga, mindfulness, and nutrition, helping users achieve their health goals. By providing comprehensive decentralized analysis, Humanoo enables companies and insurers to gain insights into the health of their employees or clients, facilitating measurable improvements. The team, comprised of 65 professionals from 15 countries, includes software developers, designers, marketing and sales specialists, as well as health and wellness experts such as sports scientists, nutritionists, yoga instructors, and physiotherapists. Humanoo's mission is to motivate individuals to maintain a healthy lifestyle and improve their overall productivity.

EPha.ch is a startup emerging from the University Hospital Zurich and the University of Zurich, focused on clinical pharmacology. The company comprises an interdisciplinary team of specialists, including pharmacists and computer scientists, who possess extensive expertise in drug therapy. EPha.ch has developed a digital AI-powered assistant that aims to prevent medication errors and enhance patient safety. By utilizing artificial intelligence and advanced algorithms, the platform evaluates the safety of polypharmacy and provides personalized medication alternatives and guidance. This enables healthcare providers to analyze and optimize medication plans for patients, ensuring timely and informed decision-making based on comprehensive drug information.

Hedera Dx is a healthcare company established on July 1, 2021, in Epalinges, Vaud, specializing in liquid biopsy solutions aimed at enhancing cancer detection and treatment. The company's innovative system enables hospital laboratories to perform clinically useful liquid biopsies independently, simplifying the process of tumor profiling. By addressing challenges related to compliance, privacy, and validation, Hedera Dx offers a streamlined experience for clinicians, facilitating early detection, therapy selection, and monitoring of cancer recurrence. This technology not only aids in reducing cancer risks but also presents opportunities to lower mortality rates and healthcare costs.